Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology (Nasdaq: KURA) has announced that its Compensation Committee granted inducement awards to nine new employees on February 3, 2025. The awards consist of nonstatutory stock options to purchase 164,000 shares of common stock under the Company's 2023 Inducement Option Plan.
The stock options have an exercise price of $8.25 per share, matching the Company's closing sales price on February 3, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over the subsequent 36 months, contingent on continued employment.
Kura Oncology (Nasdaq: KURA) ha annunciato che il suo Comitato di Compensazione ha concesso premi di incentivo a nove nuovi dipendenti il 3 febbraio 2025. I premi consistono in opzioni su azioni non statutarie per acquistare 164.000 azioni di azioni ordinarie sotto il Piano di Opzioni di Incentivo 2023 della Società.
Le opzioni sulle azioni hanno un prezzo di esercizio di $8,25 per azione, corrispondente al prezzo di chiusura delle azioni della Società il 3 febbraio 2025. Le opzioni matureranno nel corso di quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente nei successivi 36 mesi, a condizione di continuare l'impiego.
Kura Oncology (Nasdaq: KURA) ha anunciado que su Comité de Compensación otorgó premios de incentivo a nueve nuevos empleados el 3 de febrero de 2025. Los premios consisten en opciones sobre acciones no estatutarias para comprar 164,000 acciones de acciones ordinarias bajo el Plan de Opción de Incentivo 2023 de la empresa.
Las opciones sobre acciones tienen un precio de ejercicio de $8.25 por acción, coincidiendo con el precio de cierre de la empresa del 3 de febrero de 2025. Las opciones se consolidarán durante cuatro años, con el 25% consolidándose después de un año y el saldo restante consolidándose mensualmente durante los siguientes 36 meses, sujeto a la continuidad del empleo.
Kura Oncology (Nasdaq: KURA)는 2025년 2월 3일에 아홉 명의 새로운 직원에게 유인 보상을 부여했다고 발표했습니다. 이 보상은 회사의 2023년 유인 옵션 계획에 따라 164,000주의 보통주를 구매할 수 있는 비상장 주식 옵션으로 구성됩니다.
주식 옵션의 행사가격은 주당 $8.25로, 2025년 2월 3일 회사의 종가에 해당합니다. 옵션은 4년에 걸쳐 분할 소멸되며, 1년 후 25%가 소멸되고, 나머지 36개월 동안 매달 소멸됩니다. 계속 고용되는 조건을 충족해야 합니다.
Kura Oncology (Nasdaq: KURA) a annoncé que son Comité de Rémunération a accordé des prix d'incitation à neuf nouveaux employés le 3 février 2025. Les prix consistent en des options d'achat d'actions non statutaires pour acheter 164 000 actions ordinaires dans le cadre du Plan d'Option d'Incitation 2023 de la Société.
Les options d'achat d'actions ont un prix d'exercice de 8,25 $ par action, correspondant au prix de clôture de la Société du 3 février 2025. Les options prendront effet sur une période de quatre ans, avec 25 % devenant effectifs après un an et le reste devenant effectif mensuellement au cours des 36 mois suivants, sous réserve d'une continuité de l'emploi.
Kura Oncology (Nasdaq: KURA) hat bekannt gegeben, dass ihr Vergütungsausschuss am 3. Februar 2025 Anreizpreise an neun neue Mitarbeiter vergeben hat. Die Auszeichnungen bestehen aus nicht-statutären Aktienoptionen zum Kauf von 164.000 Aktien der Stammaktien im Rahmen des Anreizoptionsplans 2023 des Unternehmens.
Die Aktienoptionen haben einen Ausübungspreis von $8,25 pro Aktie, der dem Schlussverkaufspreis des Unternehmens am 3. Februar 2025 entspricht. Die Optionen werden über einen Zeitraum von vier Jahren fällig, wobei 25 % nach einem Jahr fällig werden und der verbleibende Betrag in den folgenden 36 Monaten monatlich fällig wird, abhängig von einer fortgesetzten Anstellung.
- Expansion of workforce with nine new employees indicating company growth
- Implementation of employee retention strategy through stock options
- Potential shareholder dilution from 164,000 new stock options
SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 3, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 164,000 shares of common stock to nine (9) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (the “FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and the companies anticipate submission of a New Drug Application to the FDA in the second quarter of 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors:
Patti Bank
Managing Director
(415) 513-1284
patti.bank@icrhealthcare.com
Media:
Alexandra Weingarten
Associate Director, Corporate Communications
& Investor Relations
(858) 500-8822
alexandra@kuraoncology.com
FAQ
How many shares are included in KURA's February 2025 inducement stock options grant?
What is the exercise price for KURA's February 2025 inducement stock options?
What is the vesting schedule for KURA's February 2025 inducement stock options?
How many new employees received KURA's February 2025 inducement stock options?
